Jeffrey Stein, Cidara CEO
September 21, 2022 11:10 AM EDTUpdated 05:06 PM
FDA+

San Diego an­ti­fun­gal play­er nabs pri­or­i­ty re­view for blood­stream in­fec­tion treat­ment

Aayushi Pratap

News Reporter

Cidara Ther­a­peu­tics wants to make its mark in the world of an­ti­fun­gals, and thanks to the FDA, it may get there soon.

The San Diego …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

Pfiz­er part­ners with two more Flag­ship biotechs on obe­si­ty, can­cer

When gen­er­a­tive AI meets the FDA: First dig­i­tal health ad­comm kicks off dis­cus­sion

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times